IGM-PC SERIC ANTIBODY AS A BIOMARKER OF MULTIPLE SCLEROSIS, AND A NEW ULTRASENSITIVE ELISA FOR THE DIAGNOSIS OF THIS DISEASE (Machine-translation by Google Translate, not legally binding)

• Main Authors: Muñoz Morón, Ursula, Cruz Sádaba, Maria, Escudero Lirola, Esther, Quintana, Francisco J, Rothhammer, Veit Johanne
• Format: Patent
• Language: English; Spanish
• Published: 02.07.2020
• Subjects: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIRCHEMICAL OR PHYSICAL PROPERTIES; MEASURING; PHYSICS; TESTING

Serum IgM antibody against phosphatidylcholine (IgM-PC) to be used as a biomarker of multiple sclerosis (MS) and of the different phases of this disease, especially the early CIS and EMRR phases, once experimentally verified using an ELISA technique adapted, a surprisingly high level of these antibodies in the corresponding stages of MS compared to controls, which triples the value of each cohort group, and doubles the level of serum IgM-LC antibodies from the same patients; and a new semiquantitative ELISA technique developed for the specific detection of said antibody in serum samples from potential MS patients, as a highly sensitive and accurate diagnostic method. (Machine-translation by Google Translate, not legally binding) Anticuerpo sérico IgM frente a fosfatidilcolina (IgM-PC) para ser utilizado como biomarcador de la esclerosis múltiple (EM) y de las diferentes fases de esta enfermedad, en especial de las fases tempranas CIS y EMRR, una vez constatado experimentalmente mediante una técnica ELISA adaptada, un nivel sorprendentemente alto de estos anticuerpos en las correspondientes fases de la EM respecto a los controles, que triplica el valor de cada grupo de cohorte, y que duplica el nivel de anticuerpos IgM-LC en suero de los mismos pacientes; y nueva técnica ELISA semicuantitativa desarrollada para la detección específica de dicho anticuerpo en muestras séricas de pacientes potenciales de la EM, como método de diagnóstico de alta sensibilidad y precisión.